These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
3 files

Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics

revised on 21.07.2020, 10:16 and posted on 21.07.2020, 11:51 by Andrea Dorst, Inga S. Shchelik, Daniel Schäfle, Peter Sander, Karl Gademann

Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a cation-p interaction of the aromatic moiety with an arginine residue was identified. Therefore, the variation of the substituents and concurrently changing the electronic properties of the aryl moiety represents an interesting strategy in search for new fidaxomicin analogs. Herein, we report the first semisynthetic access to new fidaxomicin analogs with varying halogen substituents via a Pd-catalyzed hydrodechlorination reaction. Subsequent iodination gave access to the first iodo-fidaxomicin derivatives, which matched or improved antibacterial properties compared to fidaxomicin against Mycobacterium tuberculosis and Staphylococcus aureus ATCC 29213.


Swiss National Science Foundation (182043)

Swiss National Science Foundation ( 31003A_153349/1)

Swiss Lung Association (2018-02)


Email Address of Submitting Author


University of Zurich



ORCID For Submitting Author


Declaration of Conflict of Interest

A patent application (WO2019135010A1, EP18150671.8A) was filed Jan 8 2018 that includes antibiotics presented in this work.

Version Notes

Updated mechanism, typos corrected, H/D exchange data